Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields, recurrence is universal, median observed survival is low at 8 months and 5-year overall survival is poor at 7%. Immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Sener, Ugur, Ruff, Michael W., Campian, Jian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266573/
https://www.ncbi.nlm.nih.gov/pubmed/35806051
http://dx.doi.org/10.3390/ijms23137046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266573/
https://www.ncbi.nlm.nih.gov/pubmed/35806051
http://dx.doi.org/10.3390/ijms23137046

Ejemplares similares